# idiopathic pulmonary fibrosis (IPF) - claude-opus-4-8

- Benchmark system: raw
- Repeat: 3
- Task type: PROGNOSIS
- Tissue / sample source: lung tissue
- Comparison or endpoint: all-cause mortality
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: Anthropic / claude-opus-4-8
- Message SHA-256: d9fe74e971569d03f1ace047ce334e08d788b93d2057913b4d42b34da6d57d2f
- Response HTTP status: 200
- Prompt tokens: 
- Completion tokens: 
- Reasoning tokens: 
- Total tokens: 
- API requests reported: 
- Elapsed seconds: 137.511
- Final benchmark system: raw; file rank 2/5; original repeat 3; model vendor: Anthropic

---
# Multidimensional Interpretation of Prognostic Transcriptomic Features in Idiopathic Pulmonary Fibrosis

## Critical Data Quality Assessment

**The majority of genes in this dataset cannot be reliably interpreted.** The first ten entries show extreme hazard ratios (HR ~10²¹ or ~10⁻²²) with P values and FDR values of exactly zero, which is statistically impossible and indicates severe technical artifacts, data corruption, or computational errors. These entries include control probes (CONTROL_A_33_P3222196, CONTROL_A_33_P3345409) and genes with biologically implausible associations. **These entries must be excluded from interpretation.**

The analysis below focuses on the remaining genes (from LOC100128226 onward) that show biologically plausible effect sizes.

---

## 1. Overall Biological Interpretation

The interpretable prognostic signature in IPF lung tissue reveals **aberrant epithelial remodeling and innate immune activation** as dominant biological themes associated with mortality risk. The transcriptomic landscape is characterized by:

- **Epithelial injury and maladaptive repair responses**: Multiple genes encoding epithelial-specific proteins, cell adhesion molecules, and secreted factors (MUC1, CEACAM6/7, PKP3, SLC34A2, SFTPB) show strong risk associations, suggesting that persistent epithelial dysfunction—rather than epithelial recovery—predicts poor outcomes.

- **Pro-fibrotic and matrix-remodeling programs**: Genes involved in ECM regulation (HTRA1, BMP6, SPP1, EFEMP1), growth factor signaling (HGF, NRG1, MET), and tissue remodeling collectively indicate that active fibrogenic signaling is linked to mortality.

- **Inflammatory and innate immune activation**: Neutrophil-associated markers (S100A12, CXCL1, CD177), chemokines (CCL7, CXCL14), and acute-phase response genes reflect ongoing inflammation that may contribute to disease progression.

- **Metabolic and oxidative stress adaptations**: The presence of enzymes involved in lipid metabolism (CYP4F3, ACOX2), amino acid transport (SLC7A11, SLC6A8), and antioxidant defense (SOD3) suggests metabolic reprogramming under chronic injury conditions.

This is **not** a signature of early-stage fibrogenesis but rather a composite of chronic epithelial failure, sustained inflammatory activation, and metabolic dysregulation in advanced disease.

---

## 2. Core Biological Programs

### Program 1: Aberrant Epithelial Differentiation and Barrier Dysfunction
**Direction**: Risk-associated (HR > 1)  
**Major supporting genes**: MUC1 (HR 2.32), CEACAM6 (HR 2.66), CEACAM7 (HR 2.31), PKP3 (HR 2.50), SLC34A2 (HR 2.27), SFTPB (HR 2.67), SFTA2 (HR 2.25), KRT17 (HR 2.19), KRT23 (HR 2.59), MAL2 (HR 2.44)  
**Pathway**: GO: Epithelial Cell Differentiation; KEGG: Cell Adhesion Molecules  
**Biological rationale**: This cluster represents genes encoding mucins, carcinoembryonic antigen-related cell adhesion molecules, plakins, and alveolar-specific proteins. In IPF, persistent expression of these markers—particularly MUC1 (a marker of epithelial stress and repair failure) and CEACAM6/7 (associated with aberrant differentiation)—indicates that epithelial cells are locked in a dysfunctional state rather than regenerating functional alveolar epithelium. The inclusion of alveolar type II markers (SFTPB, SFTA2, SLC34A2) suggests that even surviving ATII cells may exhibit altered function. PKP3, a desmosomal plakophilin, and keratins (KRT17, KRT23) further support abnormal differentiation patterns.  
**Evidence strength**: Strong. Multiple independent genes converge on epithelial dysfunction. External evidence supports MUC1 as a marker of IPF progression and epithelial injury (PMID: 25181323). CEACAM6 overexpression has been linked to aberrant repair in lung injury models.  
**Limitations**: Gene expression alone cannot distinguish whether these changes reflect causal drivers of mortality or consequences of disease severity. Cell-type composition effects (increased aberrant epithelial populations vs. transcriptional changes within individual cells) cannot be resolved from bulk tissue data.

---

### Program 2: Pro-Fibrotic Growth Factor Signaling and ECM Remodeling
**Direction**: Risk-associated (HR > 1)  
**Major supporting genes**: HGF (HR 2.93), MET (HR 2.53), NRG1 (HR 2.76), BMP6 (HR 3.04), SPP1 (HR 3.40), HTRA1 (HR 4.30), EFEMP1 (HR 2.33)  
**Pathway**: Reactome: Signaling by Receptor Tyrosine Kinases; GO: Extracellular Matrix Organization; Hallmark: TGF-beta Signaling  
**Biological rationale**: This program encompasses receptor tyrosine kinase ligands (HGF, NRG1) and their cognate receptors (MET is both a receptor and risk gene here), BMP family members, and ECM-associated proteins. HGF/MET signaling is classically considered pro-regenerative, but in IPF, sustained HGF/MET activation may reflect failed repair attempts or profibrotic reprogramming. SPP1 (osteopontin) is a well-established profibrotic matricellular protein elevated in IPF and associated with poor outcomes (PMID: 15640362). HTRA1, a serine protease that regulates TGF-β signaling and ECM turnover, shows the highest HR in this group. BMP6 and EFEMP1 (fibulin-3) further implicate ECM remodeling and disrupted morphogen signaling.  
**Evidence strength**: Strong. These genes are functionally connected through growth factor-ECM crosstalk and have individual disease associations in IPF and fibrosis models. SPP1 and HTRA1 are well-documented in IPF pathogenesis.  
**Limitations**: HGF/MET pathway is context-dependent; elevated expression may represent a compensatory response rather than a causal driver. Directionality and cell-type specificity (epithelial vs. fibroblast expression) require spatial or single-cell validation.

---

### Program 3: Neutrophil Activation and Acute Inflammatory Signaling
**Direction**: Risk-associated (HR > 1)  
**Major supporting genes**: S100A12 (HR 2.53), S100A14 (HR 2.57), CXCL1 (HR 2.99), CCL7 (HR 3.02), CXCR1 (HR 3.28), CD177 (HR 2.72), SELL (HR 2.37)  
**Pathway**: GO: Neutrophil Activation; KEGG: Chemokine Signaling Pathway; Reactome: Neutrophil Degranulation  
**Biological rationale**: This signature reflects neutrophil-associated alarmins (S100A12, a calcium-binding protein involved in innate immunity; S100A14), chemokines that recruit neutrophils and monocytes (CXCL1, CCL7), the CXCL8 receptor CXCR1, and neutrophil markers (CD177, SELL/L-selectin). While IPF is often characterized as a "Th2-skewed" disease, emerging evidence indicates that neutrophilic inflammation and innate immune activation contribute to acute exacerbations and progressive fibrosis (PMID: 26751615). The presence of multiple chemokines and receptors suggests active recruitment and retention of inflammatory cells.  
**Evidence strength**: Moderate to strong. Individual genes are well-characterized markers of neutrophil biology, and the signal is internally consistent. External evidence links neutrophilia and elevated CXCL1/CXCL8 to poor outcomes in IPF.  
**Limitations**: This program may reflect intercurrent infection, acute exacerbation events, or sampling from areas of active injury rather than chronic, stable disease biology. Without clinical annotation (time from last exacerbation, infection status), the interpretation remains ambiguous. Additionally, S100 proteins can be expressed by multiple cell types under stress.

---

### Program 4: Dysregulated Lipid and Xenobiotic Metabolism
**Direction**: Risk-associated (HR > 1)  
**Major supporting genes**: CYP4F3 (HR 3.78), ACOX2 (HR 3.18), ALDH1A3 (HR 2.27), SLC7A11 (HR 3.52), SLC6A8 (HR 3.21), SLCO4A1 (HR 2.97)  
**Pathway**: KEGG: Metabolism of Xenobiotics by Cytochrome P450; GO: Fatty Acid Beta-Oxidation; Reactome: Amino Acid Transport  
**Biological rationale**: CYP4F3 encodes a cytochrome P450 enzyme involved in leukotriene metabolism and xenobiotic processing; its elevated expression may reflect inflammatory lipid mediator production. ACOX2 is a peroxisomal acyl-CoA oxidase involved in fatty acid β-oxidation. ALDH1A3 participates in retinoid metabolism and oxidative stress responses. The solute carriers—SLC7A11 (cystine/glutamate antiporter, central to glutathione synthesis and ferroptosis resistance), SLC6A8 (creatine transporter), and SLCO4A1 (organic anion transporter)—indicate altered metabolic flux and potential adaptation to oxidative stress. SLC7A11 is particularly notable: its upregulation in cancer and fibrosis contexts is linked to antioxidant defense, but also to metabolic reprogramming that may support maladaptive cell survival.  
**Evidence strength**: Moderate. Metabolic reprogramming is increasingly recognized in fibrosis, but the specific roles of these genes in IPF are less well-defined than those of epithelial or ECM genes. SLC7A11 has direct mechanistic links to oxidative stress, a key feature of IPF pathogenesis.  
**Limitations**: Metabolic gene expression can be highly variable across individuals and may reflect systemic factors (e.g., smoking history, medication use) rather than disease-intrinsic biology. The functional consequences of elevated CYP4F3 or ACOX2 in IPF lung tissue are not well-established. Gene-level expression does not inform on enzyme activity or metabolite flux.

---

### Program 5: Cell Survival and Stress Response Signaling
**Direction**: Risk-associated (HR > 1)  
**Major supporting genes**: MARCKS (HR 4.00), BASP1 (HR 3.77), FHL2 (HR 2.76), SOD3 (HR 2.37), DYSF (HR 3.47)  
**Pathway**: GO: Response to Oxidative Stress; Reactome: PKC Signaling; GO: Regulation of Apoptotic Process  
**Biological rationale**: MARCKS (myristoylated alanine-rich C-kinase substrate) and BASP1 are PKC substrates involved in cell motility, membrane dynamics, and cytoskeletal organization; their high HRs suggest that aberrant cell motility or survival signaling may contribute to poor outcomes. FHL2 (four and a half LIM domains 2) is a scaffolding protein that regulates cell adhesion, transcription, and cytoskeletal dynamics. SOD3 (extracellular superoxide dismutase) is an antioxidant enzyme; paradoxically, its elevation in IPF may reflect compensatory upregulation in response to chronic oxidative stress, but sustained high-level expression can also indicate failure of redox homeostasis. DYSF (dysferlin) is involved in membrane repair.  
**Evidence strength**: Moderate. These genes are functionally diverse but converge on themes of cell stress, survival, and cytoskeletal dynamics. MARCKS has been implicated in fibroblast activation and migration in fibrosis models (PMID: 28490447). SOD3 is known to be upregulated in IPF lung tissue.  
**Limitations**: This is the most heterogeneous of the five programs. The functional connections are more indirect, and the biological coherence is weaker than for Programs 1–3. MARCKS and BASP1 regulate multiple downstream processes, making it difficult to pinpoint the relevant mechanism. The prognostic value may reflect diverse stressors converging on common signaling nodes.

---

## 3. Key Genes and Interaction Modules

### 1. **HTRA1** (HR 4.30)
**Statistical direction**: Strong risk association (highest HR among interpretable genes)  
**Role in core programs**: Central to Program 2 (Pro-fibrotic signaling and ECM remodeling)  
**Biological context**: HTRA1 is a serine protease that cleaves ECM components and regulates TGF-β availability and signaling. In IPF, HTRA1 may modulate fibroblast activation and matrix turnover. Its high HR suggests that elevated HTRA1 expression—or the processes it reflects—is a powerful predictor of mortality.  
**Gene relationships**: HTRA1 is co-expressed with ECM and TGF-β pathway genes in fibrosis datasets (pathway co-membership). There is no established direct physical interaction with other top genes in this list, but HTRA1 can regulate the activity of ECM-bound growth factors, indirectly affecting signaling pathways.  

---

### 2. **MARCKS** (HR 4.00) and **BASP1** (HR 3.77)
**Statistical direction**: Strong risk association  
**Role in core programs**: Program 5 (Cell survival and stress response)  
**Biological context**: Both are PKC substrates involved in membrane-cytoskeleton interactions and cell motility. MARCKS has been linked to fibroblast migration and myofibroblast differentiation in experimental fibrosis models.  
**Gene relationships**: MARCKS and BASP1 share regulatory pathways (PKC signaling) and functional roles (co-expression, pathway co-membership), but no direct physical interaction is documented. They may be co-regulated under conditions of cellular stress or fibroblast activation.  

---

### 3. **SPP1 (Osteopontin)** (HR 3.40)
**Statistical direction**: Risk-associated  
**Role in core programs**: Program 2 (Pro-fibrotic signaling and ECM remodeling)  
**Biological context**: SPP1 is a secreted phosphoprotein and matricellular protein with well-established roles in IPF. It promotes fibroblast recruitment, macrophage polarization, and ECM deposition. Elevated SPP1 in IPF lung tissue and serum is consistently associated with disease progression and mortality.  
**Gene relationships**: SPP1 is functionally connected to integrins (receptor interaction), TGF-β signaling (indirect regulatory interaction), and ECM components (pathway co-membership). It is co-expressed with other profibrotic genes in IPF datasets.  

---

### 4. **HGF** (HR 2.93) and **MET** (HR 2.53)
**Statistical direction**: Both risk-associated  
**Role in core programs**: Program 2 (Pro-fibrotic growth factor signaling)  
**Biological context**: HGF is the ligand for the MET receptor tyrosine kinase. Canonically, HGF/MET signaling promotes epithelial survival and regeneration, but in chronic fibrotic contexts, sustained activation may drive aberrant epithelial-mesenchymal crosstalk or epithelial dysfunction.  
**Gene relationships**: HGF and MET are in a direct ligand-receptor interaction. The fact that both are risk-associated suggests that the pathway as a whole—not just ligand availability—is linked to poor outcomes. This could reflect autocrine/paracrine loops or pathway dysregulation.  

---

### 5. **SLC7A11** (HR 3.52)
**Statistical direction**: Risk-associated  
**Role in core programs**: Program 4 (Dysregulated metabolism)  
**Biological context**: SLC7A11 (xCT) is the light chain of the system Xc- cystine/glutamate antiporter, critical for glutathione synthesis and protection against ferroptosis. In cancer and fibrosis, SLC7A11 upregulation supports cell survival under oxidative stress. However, excessive reliance on this pathway may also indicate metabolic vulnerability.  
**Gene relationships**: SLC7A11 is functionally connected to glutathione metabolism (pathway co-membership) and oxidative stress response genes such as SOD3 (indirect relationship through shared biological processes). No direct physical interactions with other genes on this list are established.  

---

### 6. **S100A12** (HR 2.53) and **CXCL1** (HR 2.99)
**Statistical direction**: Risk-associated  
**Role in core programs**: Program 3 (Neutrophil activation and inflammation)  
**Biological context**: S100A12 is a DAMP (damage-associated molecular pattern) that activates RAGE signaling and drives inflammation. CXCL1 is a chemokine that recruits neutrophils. Together, they suggest an active inflammatory milieu.  
**Gene relationships**: S100A12 and CXCL1 are co-expressed in inflammatory contexts (literature co-occurrence, pathway co-membership in neutrophil activation). They may be co-regulated by NF-κB signaling, but no direct physical interaction exists.  

---

### 7. **MUC1** (HR 2.32), **CEACAM6** (HR 2.66), and **PKP3** (HR 2.50)
**Statistical direction**: Risk-associated  
**Role in core programs**: Program 1 (Aberrant epithelial differentiation)  
**Biological context**: These genes are markers of altered epithelial state. MUC1 is a transmembrane mucin involved in cell signaling and barrier function; its overexpression in IPF epithelium is linked to impaired repair. CEACAM6 and PKP3 are markers of epithelial remodeling and altered differentiation.  
**Gene relationships**: Co-expression in epithelial cells (pathway co-membership in epithelial differentiation programs). No direct physical interactions are established, but they may be co-regulated by epithelial transcription factors such as p63 or FOXA2.  

---

### 8. **CYP4F3** (HR 3.78)
**Statistical direction**: Strong risk association  
**Role in core programs**: Program 4 (Metabolic dysregulation)  
**Biological context**: CYP4F3 is involved in leukotriene B4 (LTB4) metabolism. Elevated CYP4F3 may reflect increased inflammatory lipid mediator production or altered detoxification pathways in IPF lung tissue.  
**Gene relationships**: Indirect relationship with inflammatory genes through lipid mediator metabolism (pathway co-membership). No direct physical interactions with other genes in this list.  

---

### 9. **FHL2** (HR 2.76)
**Statistical direction**: Risk-associated  
**Role in core programs**: Program 5 (Cell survival and stress response)  
**Biological context**: FHL2 is a LIM-domain scaffolding protein that interacts with integrins, receptor tyrosine kinases, and transcription factors. It regulates cell adhesion, migration, and mechanotransduction—all relevant to fibroblast activation and epithelial-mesenchymal interactions in fibrosis.  
**Gene relationships**: FHL2 physically interacts with integrins and can modulate signaling downstream of growth factor receptors (direct protein-protein interactions documented in other systems). May be co-regulated with cytoskeletal and adhesion genes in the dataset.  

---

### 10. **SOD3** (HR 2.37)
**Statistical direction**: Risk-associated  
**Role in core programs**: Program 5 (Cell survival and stress response)  
**Biological context**: SOD3 is the extracellular superoxide dismutase. Paradoxically, its upregulation in IPF may reflect chronic oxidative stress rather than protective antioxidant capacity. Sustained high expression could indicate failure of redox homeostasis or compensatory responses that are ultimately insufficient.  
**Gene relationships**: Functionally connected to oxidative stress response genes such as SLC7A11 (indirect, pathway co-membership). No direct physical interactions with other top genes.  

---

## 4. Validation Priorities

### Priority 1: **HTRA1 as a Mechanistic Driver of ECM Remodeling and Fibroblast Activation**
**Classification**: Mechanistic hypothesis  
**Rationale**: HTRA1 shows the highest HR among interpretable genes and is functionally positioned at the intersection of TGF-β signaling and ECM turnover, both central to IPF pathogenesis.  
**Evidence from current dataset**: Strong statistical association (HR 4.30, FDR 2.57×10⁻⁶)  
**External evidence**: HTRA1 variants have been associated with age-related macular degeneration (another fibrotic/degenerative disease). HTRA1 regulates TGF-β signaling in vitro and in vivo. However, direct evidence for HTRA1 as a driver in IPF is limited.  
**Next step**: (1) Validate HTRA1 protein expression and localization (epithelial vs. fibroblast vs. macrophage) by immunohistochemistry or spatial transcriptomics. (2) Test whether HTRA1 knockdown or pharmacological inhibition reduces fibroblast activation or ECM deposition in IPF-relevant in vitro models (e.g., TGF-β-treated fibroblasts, precision-cut lung slices from IPF patients).  
**Conclusion status**: **Exploratory hypothesis.** The association is strong, but causality and cell-type specificity require experimental validation.

---

### Priority 2: **Neutrophilic Inflammation as a Marker of Acute Exacerbation or Progressive Phenotype**
**Classification**: Biomarker / Confounding check  
**Rationale**: Multiple neutrophil-associated genes (S100A12, CXCL1, CXCR1, CD177) are risk-associated, but it is unclear whether this reflects chronic disease biology, acute exacerbation events, or sampling bias.  
**Evidence from current dataset**: Internally consistent signature across multiple genes  
**External evidence**: Neutrophilia and elevated neutrophil chemoattractants are associated with acute exacerbations and mortality in IPF cohorts (PMID: 26751615). However, neutrophilic inflammation is not uniformly present in stable IPF.  
**Next step**: (1) Correlate neutrophil signature gene expression with clinical data: time from last acute exacerbation, forced vital capacity (FVC) decline rate, presence of infection. (2) Perform differential cell counts or flow cytometry on lung tissue or BAL to confirm increased neutrophil infiltration. (3) Test whether neutrophil signature genes predict acute exacerbation risk independently of overall disease severity.  
**Conclusion status**: **Supported hypothesis** that neutrophilic inflammation predicts poor outcomes, but **requires clinical context** to distinguish stable progressive disease from exacerbation-prone phenotypes.

---

### Priority 3: **Aberrant Epithelial Program (MUC1, CEACAM6, PKP3) as a Target for Regenerative Therapy**
**Classification**: Therapeutic target / Mechanistic hypothesis  
**Rationale**: The epithelial dysfunction signature is prominent and includes genes (MUC1) with known links to impaired repair. If these genes reflect a maladaptive epithelial state that can be reversed, this program could be therapeutically relevant.  
**Evidence from current dataset**: Multiple independent epithelial genes converge on this theme  
**External evidence**: MUC1 overexpression in IPF epithelium has been shown to impair epithelial-mesenchymal crosstalk and repair (PMID: 25181323). CEACAM6 is linked to aberrant differentiation in other lung diseases. However, these genes may be downstream markers rather than causal drivers.  
**Next step**: (1) Use single-cell RNA-seq to determine whether the aberrant epithelial signature is present in a distinct subpopulation (e.g., KRT5+ basal-like cells, transitional cells) or broadly across ATII cells. (2) Test whether MUC1 knockdown or blockade in IPF-derived epithelial cells restores normal differentiation or reduces profibrotic signaling. (3) Investigate whether existing therapies (e.g., pirfenidone, nintedanib) modulate this epithelial signature.  
**Conclusion status**: **Exploratory hypothesis.** The association is strong, but causality and therapeutic tractability are uncertain.

---

### Priority 4: **SLC7A11-Mediated Ferroptosis Resistance as a Metabolic Vulnerability**
**Classification**: Therapeutic target / Mechanistic hypothesis  
**Rationale**: SLC7A11 (HR 3.52) is a central regulator of glutathione synthesis and ferroptosis resistance. Elevated SLC7A11 may indicate that cells in IPF lung tissue are relying on this pathway to survive oxidative stress, creating a potential therapeutic vulnerability.  
**Evidence from current dataset**: Strong statistical association  
**External evidence**: SLC7A11 is upregulated in fibrotic diseases and cancer. Inhibition of SLC7A11 or system Xc- has shown efficacy in preclinical cancer models by inducing ferroptosis. In fibrosis, the role is less clear; some studies suggest that ferroptosis contributes to epithelial injury, while others implicate ferroptosis resistance in fibroblast survival.  
**Next step**: (1) Validate SLC7A11 expression at the protein level and determine cell-type specificity (epithelial vs. fibroblast vs. immune cells). (2) Test whether SLC7A11 inhibitors (e.g., erastin, sulfasalazine) or genetic knockdown induce ferroptosis in IPF-derived fibroblasts or aberrant epithelial cells. (3) Assess whether SLC7A11 inhibition reduces fibrosis in experimental models (e.g., bleomycin-induced fibrosis).  
**Conclusion status**: **Exploratory hypothesis.** The metabolic logic is compelling, but the cell-type specificity and therapeutic index require validation. **Note**: SLC7A11 inhibition may also harm normal epithelial cells, so safety must be carefully evaluated.

---

### Priority 5: **HGF/MET Pathway Dysregulation as a Failed Repair Signal**
**Classification**: Mechanistic hypothesis / Interaction hypothesis  
**Rationale**: Both HGF (ligand) and MET (receptor) are risk-associated, which is paradoxical given the canonical role of HGF/MET in epithelial regeneration. This may indicate that sustained pathway activation in IPF reflects maladaptive signaling rather than effective repair.  
**Evidence from current dataset**: Both ligand and receptor are independently associated with mortality  
**External evidence**: HGF is elevated in IPF serum and BAL fluid. MET signaling promotes epithelial survival in vitro, but chronic HGF exposure can induce epithelial-mesenchymal transition (EMT) or aberrant differentiation in some contexts. Clinical trials of HGF therapy in IPF have not shown efficacy.  
**Next step**: (1) Determine whether HGF and MET are co-expressed in the same cells (epithelial autocrine loop) or in different cell types (paracrine signaling). (2) Use phospho-proteomic or signaling pathway analysis to assess whether MET signaling is functionally active or desensitized in IPF tissue. (3) Test whether MET inhibition (paradoxically) reduces aberrant epithelial responses or fibroblast activation in IPF models.  
**Conclusion status**: **Exploratory hypothesis.** The dual association is intriguing, but the functional interpretation is uncertain. This could reflect failed repair, aberrant autocrine signaling, or compensatory upregulation in non-responsive cells.

---

## 5. Evidence Grounding

### Summary of Evidence Types Supporting Major Conclusions

| **Biological Program** | **Dataset Evidence** | **Pathway/Ontology** | **Disease Association** | **Protein Interaction** | **Literature Evidence** | **Independent Replication** |
|------------------------|----------------------|----------------------|-------------------------|-------------------------|-------------------------|-----------------------------|
| Aberrant Epithelial Differentiation | Multiple genes, consistent direction | GO, KEGG | MUC1, CEACAM6 linked to IPF | Co-expression, not direct PPI | Strong (PMID: 25181323) | Yes (MUC1 in IPF cohorts) |
| Pro-fibrotic Signaling & ECM | Multiple genes, high HRs | Reactome, Hallmark | SPP1, HTRA1 associated with IPF outcomes | HGF-MET direct interaction | Strong (SPP1: PMID: 15640362) | Yes (SPP1 in multiple IPF studies) |
| Neutrophil Activation | Consistent signature | GO, KEGG | Neutrophilia linked to exacerbations | Co-expression in inflammation | Moderate (PMID: 26751615) | Partial (acute exacerbation context) |
| Metabolic Dysregulation | Multiple genes | KEGG, Reactome | SLC7A11 in fibrosis/cancer | Indirect (pathway) | Emerging (SLC7A11 in fibrosis models) | Limited in IPF specifically
